Analysis for IDXX
- 📈 Growth — 26/30
- 💰 Profitability — 18/20
- 🏦 Financial Health — 17/20
- 💵 Valuation — 12/20
- ⚠️ Risk — 3/10
Summary:
📈 Growth & Financial Trajectory
Across 7 observed quarters (2024 Q2 to 2026 Q1), Revenues rose from about $954.3M to $1.141B, a ~19% gain, despite a mid-cycle dip in 2024 Q4 and a minor 2025 Q4 pullback. Net Income grew from $203.3M in 2024 Q2 to $278.4M in 2026 Q1, signaling durable earnings growth amid quarterly fluctuations.
💰 Margins & Cash Flow
Gross Margin remained around 60-63% and Operating Margin trended near 28-32%, reflecting strong profitability. Cash generation was robust, with positive Net Cash Flow From Operating Activities in each quarter; 2026 Q1 shows roughly $266.2M of operating cash flow, complemented by investing cash outflows and varying financing activity.
🛡️ Balance Sheet & Liquidity
The balance sheet shows a sizable asset base (~$3.3–$3.4B) and equity around ~$1.56B. Current Assets and Current Liabilities hovered around ~$1.3–$1.5B and ~$1.0–$1.3B respectively, indicating healthy liquidity and positive working capital. Debt remains moderate in earlier quarters.
⚠️ Key Drivers & Risks
- Drivers: Core animal-health diagnostics demand and IDEXX's integrated lab and software ecosystem.
- Risks: Revenue cyclicality in pet health spend and potential valuation sensitivity if quarterly momentum slows; modest currency/liquidity risks given USD reporting.